Drug Database
SI

sirolimus (NPC 12G / Hyftor / rapalimus)

✓ Approved

Nobelpharma Co., Ltd. · MTOR

什么是 sirolimus?

sirolimus 是一种治疗药物,由Nobelpharma Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名NPC 12G, Hyftor, rapalimus
公司Nobelpharma Co., Ltd.
分子靶点MTOR
给药途径Topical
状态Approved

作用机制

分子靶点

sirolimus 作用于 1 个分子靶点:

MTORmechanistic target of rapamycin kinase (FRAP2, RAPT1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

sirolimus 针对 4 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Angiofibroma✓ Approved
Respiratory, thoracic and mediastinal disordersLymphangioleiomyomatosis✓ Approved
Congenital, familial and genetic disordersLymphatic malformation✓ Approved
Congenital, familial and genetic disordersNeurofibromatosisPhase III

相关研究文献

PubMedThe Journal of dermatological treatment2026-11-19

Treatment outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma: a single-center retrospective cohort study.

Tian Yi Y, Wei Li L, Li Li L, Ma Lin L

To describe outcomes and safety of oral β-blockers and sirolimus in children with kaposiform hemangioendothelioma (KHE). We retrospectively reviewed children with KHE receiving oral β-blockers or sirolimus at Beijing Children's Hospital from January 2016 to April 2026. Lesion regression at fixed time points, treatment duration, treatment discontinuation, recurrence, and safety were assessed. Thirteen patients received β-blockers and 11 sirolimus, including three with prior therapy. Baseline lesion measurements did not differ significantly, but the β-blocker group was younger [median 4.0 (IQR, 3.0-4.0) vs. 19.0 (10.5-29.5) months; p < 0.001] and had lower frequencies of pain (23.1% vs. 72.7%; p = 0.038) and hyperhidrosis (0% vs. 54.5%; p = 0.003). Cumulative lesion-regression thresholds did not differ significantly through 9 months. At 9 months, >25%, >50%, and >75% regression occurred in 76.9%, 46.2%, and 23.1% with β-blockers versus 100.0%, 72.7%, and 18.2% with sirolimus, respectively. Treatment was discontinued in 9/13 and 3/11 patients (median durations, 40.0 and 18.0 months, respectively). No recurrence was observed after cessation. Safety events were reversible and manageable. In this cohort, both treatments were associated with improvement, but baseline imbalances limit direct comparison. β-blocker responses in predominantly younger, less symptomatic patients require confirmation in larger prospective studies.

PMID 43053660
阅读全文 →
PubMedJournal of pediatric gastroenterology and nutrition2026-11-18

Long-term outcome of dietary therapy in primary intestinal lymphangiectasia: Are we achieving sustained remission? A national retrospective study.

Renzo Sara S, Naldini Sara S, Dalpiaz Irene I, Scarallo Luca L et al.

Primary intestinal lymphangiectasia (PIL) is a rare congenital malformation causing protein-losing enteropathy. Given limited data on long-term dietary outcomes, this study describes clinical features, dietary response durability, and second-line therapies in an Italian pediatric cohort. This multicenter retrospective study (2012-2025) analyzed children with PIL. Complete clinical remission required symptom resolution, normalized serum albumin, and intravenous albumin independence. Endoscopic and histological remissions were defined as the absence of macroscopic alterations and lymphatic vessel dilatation, respectively. Eighteen patients were included (median onset/diagnosis: 9 and 16 months, respectively). Key symptoms were ascites (82.4%), peripheral edema (76.5%), and lymphedema (64.7%); 94.1% showed profound hypoalbuminemia, hypoproteinemia, and hypogammaglobulinemia. Endoscopy revealed "snowflake" mucosa in 86.7%. Although all started a low-fat, high-protein medium-chain triglycerides diet, only 27.7% (5/18) achieved sustained complete remission on diet alone. Due to dietary failure, 55.6% (10/18) required second-line treatments (octreotide, sirolimus), with limited remission rates (1/4 and 2/7, respectively); one refractory child achieved remission with everolimus after sirolimus failure. At a median 5-year follow-up, endoscopic and histological remissions were reached in 54.5% (6/11) and 57.1% (4/7) of re-evaluated patients. PIL poses significant therapeutic challenges. Our findings show a loss of response to dietary management over time in a subset of patients, requiring tailored second-line pharmacological interventions whose management currently relies on limited clinical experiences in refractory cases.

PMID 43046795
阅读全文 →
PubMedArquivos brasileiros de cardiologia2026-11-18

Real-World 2-Year Outcomes of the Inspiron™ Biodegradable Polymer Sirolimus-Eluting Stent.

Soccol Ricardo Czarnobai RC, Ribeiro Henrique Barbosa HB, Lasevitch Ricardo R, Pellegrini Denise D et al.

The Inspiron™ sirolimus-eluting stent (SES) is a third-generation coronary stent featuring thin struts and an abluminal biodegradable polymer coating. Although it is widely used in Brazil, long-term real-world evidence remains limited. To evaluate the safety and effectiveness of the Inspiron™ SES over 24 months in an unselected population undergoing percutaneous coronary intervention (PCI). This pooled analysis included 2,803 consecutive patients who underwent Inspiron™ SES implantation between June 2017 and January 2022 at 25 Brazilian centers. The primary endpoint was major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, MI, and target lesion revascularization (TLR) at 24 months. Kaplan-Meier survival analysis, Cox proportional hazards regression, and restricted cubic spline models were used. A two-sided p-value < 0.05 was considered statistically significant. At 24 months, the cumulative incidence of MACE was 6.7%, with rates of 5.4% for all-cause mortality, 2.3% for cardiovascular mortality, 1.2% for MI, 0.9% for TLR, and 0.6% for definite or probable stent thrombosis (ST). Patients with a vessel diameter < 2.5 mm had significantly higher rates of MACE, cardiovascular death, repeat revascularization, and ST (p = 0.022). Independent predictors of MACE included older age (p = 0.034), left main or three-vessel coronary artery disease (p = 0.024), and acute coronary syndrome as the indication for PCI (p < 0.001). In this large real-world registry, the Inspiron™ SES demonstrated favorable safety and effectiveness through 24 months, with low rates of ST and repeat revascularization despite the inclusion of complex coronary lesions.

PMID 43049007
阅读全文 →
PubMedAutoimmunity2026-11-17

Sirolimus is associated with longer relapse-free survival than cyclosporine in autoimmune hemolytic anemia and evans syndrome: a retrospective cohort study.

Zhang Yang Y, Wan Jiajun J, Luo Guanyu G, Zhang Ziying Z et al.

This single-center retrospective cohort study compared sirolimus plus glucocorticoids with cyclosporine plus glucocorticoids in 37 and 35 patients with autoimmune hemolytic anemia/Evans syndrome, evaluating treatment response, long-term relapse, and exploratory patient-reported outcomes (PROs). Response and relapse were assessed longitudinally, and relapse-free survival was analyzed using time-to-event methods. PRO data (SF-36/HADS/FACIT) were available only for subsets of the sirolimus cohort and were not collected in the cyclosporine group. No statistically significant differences in overall or complete response rates were detected between the sirolimus (78.4% and 47.3%) and cyclosporine (80.0% and 52.8%) groups (P > 0.05). Median relapse-free survival was not reached in the sirolimus group versus 1455 days in the cyclosporine group (P < 0.05), and the overall relapse rate was lower (16.2% vs. 35.0%; P < 0.05). These findings are hypothesis-generating given the nonrandomized design, small heterogeneous cohort, baseline imbalances, and incomplete drug-level monitoring, and require confirmation in prospective studies.

PMID 43040635
阅读全文 →
PubMedCardiovascular and interventional radiology2026-11-16

Nonoperative Management of a Chylous Mesenteric Lymphatic Malformation Using Sclerotherapy and Sirolimus.

Yu Jay J, Motta-Leal-Filho Joaquim M JM, Sharathkumar Anjali A AA, Andrade Gustavo H V GHV et al.

PMID 43037659
阅读全文 →
PubMedAnais brasileiros de dermatologia2026-11-16

Topical sirolimus for pediatric facial inflammatory linear verrucous epidermal nevus: a case report and review of literature.

Gomide Luciana Vilela LV, Ianhez Mayra M, Miot Hélio Amante HA, Criado Paulo Ricardo PR

PMID 43038833
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多sirolimus